Two dose‐ranging studies with PF‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|17|8|751-759

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.17, Iss.8, 2015-08, pp. : 751-759

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Empagliflozin as add‐on to metformin in people with Type 2 diabetes

By  

DIABETIC MEDICINE, Vol. 32, Iss. 12, 2015-12 ,pp. : 1555-1567

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 591-598

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 581-590

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan

By Hanif W.  

Current Medical Research and Opinion, Vol. 29, Iss. 7, 2013-07 ,pp. : 807-811

Informa Healthcare

Access to resources Recommend Favorite

Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany

By Göke R.   Gruenberger J. B.   Bader G.   Dworak M.  

Current Medical Research and Opinion, Vol. 30, Iss. 5, 2014-05 ,pp. : 785-789

Informa Healthcare

Access to resources Recommend Favorite